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We report a freely available software program, Py-
romaker, which generates simulated traces for py-
rosequencing results based on user inputs. Simu-
lated pyrograms can aid in the analysis of complex
pyrosequencing results in which various hypothe-
sized mutations can be tested, and the resultant pyro-
grams can be matched with the actual pyrogram. We
validated the software using the actual pyrograms for
common KRAS gene mutations as well as several mu-
tations in the BRAF, GNAS, and p53 genes. We dem-
onstrate that all 18 possible single-base mutations
within codons 12 and 13 of KRAS generate unique
pyrosequencing traces and highlight the distinctions
between them. We further show that all reported
codon 12 and 13 complex mutations produce unique
pyrograms. However, some complex mutations are
indistinguishable from single-base mutations. For
complicated pyrograms, Pyromaker was used in two
modes, one in which hypothesis-based simulated py-
rograms were pattern-matched with the actual pyro-
grams. In a second strategy with only the pyrogram,
Pyromaker was used to identify the underlying muta-
tion by iteratively reconstructing the mutant pyro-
gram. Either strategy was able to successfully identify
the complex mutations, which were confirmed by
cloning and sequencing. Using two examples of KRAS
codon 12 mutations (specifically GGT¡TTT, G12F and
GGT¡GAG, G12E), we report which combinations of
five approaches permit unambiguous mutation iden-
tification. The most efficient approach was found to
be pyrosequencing with Pyromaker. (J Mol Diagn
2012, 14:149-159; DOI: 10.1016/j.jmoldx.2011.12.001)
Strategies to detect mutations in the molecular diagnostic
laboratory include pyrosequencing and Sanger sequenc-
ing. Dye-terminator Sanger sequencing can provide read
lengths of up to 800 bases, but has a limit of detection ofonly 20% mutant alleles, depending on sequence con-
text. Sanger sequencing results also can be ambigu-
ous for some mutations, for example, whether mutation
of two adjacent nucleotides in a sequencing trace is
due to a single allele bearing both mutations or two
alleles with one mutation each. Pyrosequencing is a
newer “sequencing-by-synthesis” technology, in which a
DNA polymerase adds a deoxynucleotide-triphosphate
(dNTP) into an elongating strand, thereby liberating a
molecule of pyrophosphate.1–3 Through a series of enzy-
matic reactions, the pyrophosphate is converted to ATP,
a co-factor in the light-producing luciferase reaction. In-
jection of the next dNTP then occurs, and the presence or
absence of light indicates whether the polymerase was
able to extend the nascent strand with the injected dNTP.
Compared to Sanger sequencing, pyrosequencing is in-
herently more quantitative and has a superior limit of
detection (5% minor allele frequency).4,5 However, py-
rosequencing does not do as well at sizing long ho-
mopolymeric repeats (eg, differentiating eight from nine
uninterrupted adenines), and its read length is shorter
than with Sanger sequencing. Pyrograms of complex mu-
tations can yield confusing patterns that are often difficult
to resolve without further investigation.
The KRAS proto-oncogene encodes the Kirsten rat
sarcoma viral oncogene homolog (K-ras), a small G-pro-
tein identified in the early 1980s.6,7 The K-ras protein
normally switches between active and inactive conforma-
tions, but activating mutations produce a protein that is
constitutively activated, and these play an important role
in the pathogenesis of a variety of tumors including colo-
rectal, lung, and pancreatic adenocarcinomas, among
others.8–11 Clinical tests to detect KRAS mutations were
quickly adopted into routine clinical testing because they
predict the lack of response to epidermal growth factor
receptor (EGFR) inhibitor therapy.12,13 Anti-EGFR mono-
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JMD March 2012, Vol. 14, No. 2clonal antibodies such as cetuximab or panitumumab are
currently used in patients with metastatic colorectal can-
cer, whereas anti-EGFR tyrosine kinase inhibitors such as
erlotinib and gefitinib are used to treat non–small-cell
lung cancer patients. However, since the K-ras protein is
distal to EGFR in the signaling cascade, activating KRAS
mutations cause resistance to anti-EFGR therapy.12–15
Recently, it was reported that colorectal cancers with a
specific codon 13 KRAS mutation (G13D) retain sensitiv-
ity to cetuximab, suggesting that the simple paradigm
that any activating KRASmutation causes resistance may
not be correct, and emphasizing the need to identify the
specific mutated base in a given patient’s tumor.16
We present a software program, named Pyromaker,
which produces simulated pyrograms. It was primarily
developed to assist in interpreting complex pyrograms.
In this report, we validate Pyromaker by comparing virtual
pyrograms to actual pyrograms for several genes. For
example, we show that all possible single-base substitu-
tion mutations within codons 12 and 13 of the KRAS gene
generate qualitatively or quantitatively unique pyrograms.
All currently reported complex mutations of these codons
also generate unique pyrograms from each other; how-
ever, some complex mutations are indistinguishable from
some single-base mutations. We present two complex
pyrograms that were impossible to interpret initially, and
used five approaches to resolving them: Sanger se-
quencing, Pyromaker hypothesis testing, Pyromaker iter-
ative mutation re-creation, melting curving analysis, and
TA cloning with Sanger sequencing.
Materials and Methods
Pyromaker
The general features of the software are reported in the
results section. The proper peak morphology was emu-
lated as a linear increase to the maximum followed by
decay phase predicted by taking the Gaussian curve
from the maximum point to four standard deviations. This
piecewise function and the SD was chosen based on
visual comparisons of the measured pyrograms against
the virtual peak widths.
Pyromaker is a Web-based application that uses an
HTML/JavaScript client interface to collect and to validate
user input. If the Web browser being used does not
support JavaScript or simply has JavaScript disabled,
instructions in English are provided. Once the form is
submitted, the data are revalidated and pre-processed
using PHP. If all supplied input passes validation, PHP
calls a script written in R to generate the appropriate
pyrogram, which is returned to the user in PDF format.
The Web version of Pyromaker is executed on a server
running the latest version of Ubuntu (10.4 long-term sup-
port, 5/1/10).
Validation of the mutations was performed by the fol-
lowing: i) visually comparing the virtual pyrograms
against clinical pyrosequencing data for a spectrum of
KRAS mutations; ii) computing the virtual traces for all
theoretically possible single point mutations in codons 12and 13; iii) generating the predicted traces for all re-
ported complex mutations in the Catalogue Of Somatic
Mutations In Cancer (COSMIC) at the Sanger Institute
(http://www.sanger.ac.uk/genetics/CGP/cosmic, last ac-
cessed May 26, 2011) for KRAS codons 12 and 13; and iv)
comparing an assortment of pyrograms against those gen-
erated by pyrosequencing of other genes.
All virtual pyrograms discussed here were plotted as-
suming heterozygosity of the mutant allele and a tumor
cellularity of 50% (mutant allele frequency 25%), similar
to the peak heights in the actual data from the two exam-
ples highlighted. In hypothetical examples containing two
mutations, the mutations were assigned equal propor-
tions of the mutant DNA (mutant allele frequency 12.5%
each).
Sample Preparation and DNA Extraction
After H&E-stained slide review and tumor tissue selec-
tion, the corresponding tissue from five unstained, 5-m-
thick tissue sections was manually microdissected using
Pinpoint reagents according to the manufacturer’s proto-
col (ZymoResearch, Orange, CA). DNA was purified from
the sample using QIAmp DNA kit (Qiagen, Valencia, CA)
and quantified by OD 260 nm.
Pyrosequencing
Samples were PCR amplified using the KRAS v2.0 kit
(Qiagen, Valencia, CA) according to the manufacturer’s
protocol. The amplicons were sequenced using the
PyroMark Q24 (Biotage, SE) with PyroMark Gold re-
agents (Qiagen) containing 0.3 mol/L sequencing
primer and annealing buffer. The nucleotide dispensation
order for codons 12 to 14 was 5=-TACGACTCAGATCG-
TAG-3=, ie, where the nucleotide triphosphates (dTTP,
then dATP, then dCTP, etc) are simply listed as single
characters in a sequence (ie, TAC. . .). Dispensation or-
der is the order in which dNTPs are sequentially injected
into the reaction chamber and is optimized based on the
gene sequence (eg, for KRAS to determine whether a
mutation is in the first (12a) G or the second (12b) G in the
codon 12 sequence GGT). A position refers to one dNTP
injection/dispensation on the x axis.
Sanger Sequencing
PCR amplification reactions included 5=-AAGGCCTGCT-
GAAAATGACTG-3= (forward) and 5=-GGTCCTGCAC-
CAGTAATATGCA-3= (reverse) and were amplified in a
Veriti Thermal Cycler (Applied Biosystems/AB, Foster
City, CA) as follows: 95°C for 15 minutes, 42 cycles of
95°C for 20 seconds, 53°C for 30 seconds, and 72°C for
20 seconds, and 72°C for 5 minutes. Then the products
were purified using ExoSAP-IT (GE Healthcare), se-
quenced using the forward or reverse PCR primers and
Big Dye v3.1 reagents (AB), products purified with Big
Dye XTerminator reagents (AB), and automated se-
quencing performed by capillary electrophoresis on an
AB3130xl (AB). Sequences were aligned and examined
by visual inspection of the electropherogram, using Se-
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tion, Ann Arbor, MI).
Melting Curve Analysis
Melting curve analysis was adapted from the method
reported by Wallen et al.17 Briefly, reaction mixture con-
sisted of LightCycler FastStart DNA Master Hybridization
Probes Mix (Roche, Indianapolis, IN), 500 nmol/L For-
ward Primer (5=-AAGGCCTGCTGAAAATGACTG-3=), 100
nmol/L Reverse Primer (5=-GGTCCTGCACCAGTAATAT-
GC-3=), 400 nmol/L Sensor Probe (5=-Rox-TGCCTACGC-
CACCAGCTCCAA-Phos-3=), 200 nmol/L Anchor Probe
(5=-CCACAAAATGATTCTGAATTAGCTGTATCGTCAAG-
GCACT-FAM-3=), and 100 nmol/L peptide nucleic acid
(PNA, 5=-NH2-CCTACGCCACCAGCTCC-COOH-3=). Re-
actions were amplified in a Veriti Thermal Cycler as fol-
lows: 95°C for 10 minutes, and 45 cycles of 95°C for 10
seconds, 61°C for 10 seconds, and 72°C for 15 seconds.
Melting curve analysis was performed on the StepOne
Plus instrument (AB) through one cycle of 95°C for 20
seconds and 45°C for 60 seconds, and ramp to 78°C at
0.4°C per second. Melting curves were generated using
the StepOne Plus software (AB). Controls included a wild-
type sample (GGT and GGC for codons 12 and 13 re-
spectively) and one with a G13b G¡A single-base sub-
stitution (GAC, G13D).
TA Cloning and Sequencing
Samples were PCR amplified as described for Sanger
sequencing. Following amplification, fresh PCR products
were cloned using the pcDNA 3.3-TOPO TA cloning Kit
(Invitrogen, Carlsbad, CA), transformed into One Shot
TOP10 chemically competent Escherichia coli, and plated
on LB-ampicillin plates according to the manufacturer’s
protocols. Sets of colonies from each transformation were
picked and cultured overnight in LB medium containing
100 g/mL ampicillin. Plasmid DNA was isolated by
using PureLink Quick Plasmid Miniprep kit (Invitrogen),
Sanger sequenced using the CMV forward primer and
BigDye V3.1 reagents, and resolved on an AB3700
instrument (AB). Sequences were aligned and exam-
ined by visual inspection of the electropherogram, us-
ing Sequencher. Up to 30 colonies had to be analyzed
in some cases because of the presence of primer
dimers and wild-type alleles. Two or more clones bear-
ing the KRAS mutations were identified in controls and
for each case.
Results
Pyromaker was devised to accept the following parame-
ters: the percent tumor and normal cells, the wild-type
sequence, the dispensation order, and any number of
mutant sequences with their relative abundances and
zygosity. Using the percent tumor cells and whether the
mutation is homozygous or heterozygous, it calculates
the relative mutant and wild-type allele percentages.
These percentages are then used to generate the ex-pected signal at each point during the dispensation se-
quence and Pyromaker then produces a virtual trace of
the expected pyrogram. The signal generated by addi-
tion of the ATP analog, dATPS (hereafter simply
dATP, or A) was set to 110% of the other dNTPs, as the
addition of this base in actual pyrograms gives consis-
tently higher peak heights than those measured after
the addition of other bases. Graphs were produced
automatically for each set of parameters by the graphical
tools available in R. Additional details are provided in
Materials and Methods. Pyromaker has been made avail-
able as a free, publicly available program (http://pyromaker.
pathology.jhmi.edu).
Validation of Pyromaker
We first validated the Pyromaker software against actual
pyrograms containing common KRAS mutations. Supple-
mental Table S1 (available at http://jmd.amjpathol.org)
lists the 10 KRAS mutations for which the virtual and
actual pyrograms have been compared. After running
Pyromaker using the diagnosed mutation, the actual py-
rogram and the virtual pyrogram were compared, and all
were qualitatively identical for all mutations tested.
We also validated Pyromaker using the V600E muta-
tion in BRAF, for which the actual pyrogram (see Supple-
mental Figure S1A at http://jmd.amjpathol.org) is qualita-
tively similar to the Pyromaker generated virtual pyrogram
(see Supplemental Figure S1B at http://jmd.amjpathol.
org). Similarly we validated the software for the R201H
GNAS oncogene mutation (see Supplemental Table S1 at
http://jmd.amjpathol.org, reference 38) and for two mu-
tations in the p53 tumor suppressor gene (R248W and
R282W; see Supplemental Table S1 at http://jmd.
amjpathol.org, reference 39). The magnitude of the mu-
tations detected was well above the coefficient of varia-
tion, estimated as less than 5% (see Supplemental Table
S2 at http://jmd.amjpathol.org).
All Codon 12 and Codon 13 KRAS Single-Base
Mutations Produce Distinct Pyrograms
After having validated Pyromaker for the above muta-
tions, we produced pyrograms for all possible base
substitution mutations in codon 12 (Figure 1), and all
mutations gave distinct patterns. We considered two
pyrograms to be qualitatively similar if they contained
the peaks at the same positions, albeit at different
heights. Pyrograms for many of the mutations are qual-
itatively distinct; however GAT and GGA mutations
(mutated bases underlined, Figure 1, panels with short
dashed borders) are qualitatively similar, in that both
have the novel A peak compared to the wild-type trace.
However, they are quantitatively distinct in that, with
the GAT trace, the novel A activity is associated with
loss of preceding G activity (see down arrow), whereas
for the GGA mutation, the A activity is associated with
a reduction of the subsequent T peak (see down ar-
row). Asterisks highlight peaks that distinguish two
qualitatively similar pyrograms. Similarly GCT and
ows. (T
umor ce
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tively similar, but for the GCT mutation, the novel C
activity derives from the preceding G, whereas for
GGC mutation, the C activity is associated with loss of
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Figure 1. KRAS codon 12 mutations. Virtual pyrograms for wild type (GGT
mutations are qualitatively distinct from wild type and all of the other mutatio
versus GGA, short dashed line borders); GCT versus GGC, long dashed line b
peaks that should not be present or peaks that are too high; down arrows in
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JMD March 2012, Vol. 14, No. 2Similar to codon 12, all single-base codon 13 base
substitution mutations are also either qualitatively or
quantitatively distinct (Figure 2). GCC and TGC are most
similar to the wild-type trace, as they do not generate any
novel peaks (three panels with dotted borders). They are
easily distinguished however, because with the GCC mu-
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JMD March 2012, Vol. 14, No. 2the latter derives from the subsequent C. As discussed,
distinguishing the G13D mutation may be clinically im-
portant (as discussed in introductory section of text). The
GGG, GTC, and GGT traces (panels with long dashed
borders) all contain the same novel T peak, but the GGG
mutation has an increase in G activity preceeding, and
loss of C, G, and T activities following the novel T peak. In
contrast, for the GTC mutation, the extra T activity derives
from the preceding G, whereas with the GGT mutation,
the extra T activity is associated with loss of subsequent
C peak activity. A similar analysis was performed for the
less frequently reported codon 61 (see Supplemental
Figures S2 and S3 at http://jmd.amjpathol.org) and
codon 146 mutations (see Supplemental Figure S4 at
http://jmd.amjpathol.org).
All Reported Codon 12 and Codon 13 KRAS
Complex Mutations Produce Pyrograms Distinct
from One Another
Interrogation of the Cosmic database at the Sanger Insti-
tute for all reported complex (two-base) mutations of
KRAS codons 12 and 13 revealed 11 complex codon 12
mutations and 9 complex codon 13 mutations. Virtual
pyrograms for all of the codon 12 mutations (see Supple-
mental Figure S5 at http://jmd.amjpathol.org) demonstrate
that, similar to the single-base changes, many traces are
qualitatively unique, in that novel peaks are unique to that
one mutation. The most qualitatively similar are GAA and
GAG (panels with dotted borders), TTT and TGG (short
dashed borders), in addition to ATT and AAT (long
dashed borders); however, each of these pairs can be
quantitatively distinguished (asterisks). These results are
provided for other investigators to use for pattern match-
ing complex pyrograms. Similarly, all of the codon 13
mutations (see Supplemental Figure S6 at http://jmd.
amjpathol.org) could be distinguished from one another
either qualitatively or quantitatively. Only GAA and GAG
(panels with dotted borders), in addition to GTG and GTT
(dashed borders) are qualitatively similar and need to be
quantitatively distinguished.
Some Mutations Produce Identical Pyrograms
Using the Default KRAS Dispensation Order
Comparing pyrosequencing traces for single-base
changes (Figures 1 and 2) to complex mutations (see
Supplemental Figures S5 and S6 at http://jmd.amjpathol.
org) raises some concerns. For example, AGT (Figure 1)
and AAT (see Supplemental Figure S5 at http://jmd.
amjpathol.org) show the same pattern of peaks, where the
increased A activity is accompanied by the same amount
of decrease in G peak activity. Although these traces are
slightly different using our default parameters, they can
be made to look identical by varying the percent tumor
cellularity (not shown). We demonstrated that these two
sequences could be distinguished if an additional dTTP
were dispensed after the A and before the G (not shown).
A similar problem would likely occur, distinguishing CGT
from CCT; however CCT for codon 12 has not yet beenreported in Cosmic, and similarly, these could be distin-
guished by dispensing a T after the C and before the G.
Some codon 13 mutations also are indistinguishable
using the current default dispensation. AGC (Figure 2)
and AAC (see Supplemental Figure S6 at http://jmd.
amjpathol.org) are similar and can be made to be identi-
cal by varying percent tumor cellularity or zygosity (not
shown). A similar situation would be expected for TGC
and TTC, although the TTC mutation has not been re-
ported. Similar to codon 12, these mutations could be
distinguished using a different dispensation order, de-
signed to exaggerate sequence differences.
A Single Sequencing Approach Can Yield
Ambiguous Results for Complex Cases
Paraffin-embedded tissue section samples from two pa-
tients with colon adenocarcinoma were tested for KRAS
mutation analysis to guide chemotherapy selection. Py-
rosequencing of KRAS codons 12 and 13 was initially
performed, but the pyrograms could not be interpreted.
Compared to the wild type (Figure 3A), there are three
signature changes in the pyrogram for case 1, namely,
extra T, C, and T peaks (Figure 3B, numbered). Reduc-
tions of peak heights at other positions are also noted
(arrowheads). For case 2, the four signature changes are
a reduction of a G peak, an extra A peak, a reduction of
a T peak, and an increased G peak (Figure 3C, arrows,
numbered).
To clarify the complex pyrosequencing data, the sam-
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Figure 3. Complex pyrosequencing results for two KRAS mutation cases. A:
Pyrogram for wild-type KRAS. B: Pyrogram for case 1. Note the three novel
“signature peaks,” T, C, and T (arrows, numbered) that are not present in the
wild-type pyrogram. Reduction of peak height at other positions is noted
(arrowheads). 1X and 2X are determined by the peak height of bases where
the mutant and normal alleles are in register (distal to the region shown in the
figure). C: Pyrogram for case 2. Note the four signature peaks (arrows,
numbered) unique to this mutation. Horizontal lines designate the expected
1X and 2X activities. Wild-type activity is present for both cases (due to
stromal cells and the remaining wild-type allele in the cancer cells).ples were reamplified and sequenced by the Sanger
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revealed mutations of two adjacent nucleotides of codon
12 for both cases (Figure 4, B and C, arrowheads), com-
pared to the wild type (Figure 4A). Wild-type bases are
also present at these positions, which is not surprising, as
tumors contain non-neoplastic stromal cells and because
activating KRAS mutations are usually heterozygous in
malignant cells. However, Sanger sequencing alone can-
not elucidate whether the mutations are on the same
allele or on two different alleles. For case 1, there could
be a two-base TTT mutation on a single allele (from wild-
type codon 12 GGT) or a mixture of two single nucleotide
mutations (TGT and GTT) on two separate alleles (Figure
4B, hypotheses shown on the right). Similarly, the Sanger
sequencing results for case 2 may be due to a two-base
mutation producing a single GAG allele or due to a mix-
ture of two alleles (GAT and GGG), as illustrated in Figure
4C. Repeat analysis of the pyrogram, with the knowledge
of the Sanger sequencing, indicates the two base muta-
tion on one allele is the only solution, as described for
case 1 in Supplemental Figures S7 and S8 (available at
http://jmd.amjpathol.org). However, an unambiguous so-
lution from either sequencing strategy alone, is either
impossible (Sanger sequencing) or extremely difficult
(pyrosequencing).
Software Analysis
Hypothesis-Based Pattern Matching
To resolve the ambiguity that exists for the pyrose-
quencing results, we used Pyromaker, in hypothesis test-
ing mode. If one is entertaining two alternative hypothe-
ses, one can enter each of them and then pattern-match
the computer-generated pyrograms to the actual data.
The wild-type pyrosequencing pattern generated by the
computer program (Figure 5A) closely matched the ac-
tual wild-type pyrogram (Figure 3A). We then tested the
two hypotheses for the first case, and the pyrosequenc-
ing pattern for TTT generated by the software qualitatively
matched the actual clinical data where all three novel
G C T G G T G G C G T A 
T  T 
   A  G 
Hypothesized 
Mutations 
TTT 
 vs. 
TGT /GTT 
GAG 
 vs. 
GAT/GGG 
12 13 
G C T G G T G G C G T A 
G C T G G T G G C G T A 
Wild type 
Case 1 
Case 2 
A
B
C
Figure 4. Sanger sequencing results and hypotheses generated. A: Sanger
sequence for wild-type KRAS. B: Sanger sequence for case 1 and alternate
hypotheses to explain the sequencing results are listed. Mutant bases are
underlined. C: Sanger sequence for case 2 and hypotheses. Arrowheads
indicate the mutant peaks compared to the wild-type sequence. Codons 12
and 13 are bracketed.peaks in the actual pyrogram are present (compare Fig-ure 5B, left panel, versus Figure 3B). The alternative
hypothesis of two single-base mutations, TGT/GTT, on
two separate alleles (Figure 5B, right panel) generated a
pattern clearly distinct from Figure 3B. Similarly, for the
second case, the GAG mutation (Figure 5C, left) qualita-
tively matched the four signature peaks (generated by
the mutation) in the pyrogram for case 2 (Figure 3C),
whereas a mixture of GAT/GGG alleles clearly did not
(Figure 5C, right).
Iterative Approach
Alternatively, Pyromaker can be used to identify the
mutated bases where the user iteratively adds putative
mutated bases to the wild-type pyrogram to ultimately
reproduce a given pyrogram. This can be done from just
the pyrosequencing result by itself, without using Sanger
sequencing data to first generate hypotheses. As dis-
cussed, the pyrogram for the first case contains three
2X 
1X 
Dispensation Sequence 
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Figure 5. Pyromaker-generated pyrosequencing traces, hypothesis-testing
mode. Simulated pyrosequencing traces for wild-type KRAS (A), the two
hypotheses for case 1 (B), and the two hypotheses for case 2 (C). Only those
peaks that correspond to signature peaks identified in Figure 3 are num-
bered. Arrowheads indicate peaks that are not consistent with the experi-
mental data (peaks that are either novel or not the appropriate height).
eaks id
not the
156 Chen et al
JMD March 2012, Vol. 14, No. 2signature peaks in the pyrogram (Figure 3B). To obtain
the first T peak (#1) ahead of the wild-type G, the mini-
mum mutation needed is TGT (Figure 6A, far left); how-
ever, the resultant pyrogram does not include the other
two signature peaks. To advance the polymerase and to
obtain the C peak (#2 in Figure 3B) ahead of the wild-type
T, and without inducing any other new peaks or frame-
shifting the gene, one must replace the G in the 12b
position (TGT) with a second T to move the G activity
(which otherwise blocks the polymerase from advancing)
into the T position (ie, TTT, Figure 6A, middle-left). Alter-
natively, the T in the 12c position (TGT) can be replaced
with a G to produce a run of 4 Gs (TGG/GGC, codons
12/13, Figure 6A, middle-right), thereby moving the T
activity into the G position. Both of these produce the
three signature peaks in the clinical pyrogram (Figure
3A), but only the TTT pyrogram contains the novel peaks
at the correct peak height ratios (3:1:1, respectively). A
third potential solution is TGC (Figure 6A, far right), which
produces peaks #1 and #2, but not peak #3.
Similarly for case 2, the simplest way to reduce the G
peak (Figure 3C, #1) and create the A peak (#2) before
the T peak (#3) is a 12b G¡A to produce a GAT (Figure
6B, left). (A 12a G¡A, AGT, would manifest as an A peak
ahead of the first G peak.) However, this single change to
GAT does not produce changes #3 and #4 in Figure 3C.
To reduce the T (#3) and increase the G activity (#4), a
12c T¡G might occur to produce a GAG (Figure 6B,
middle). Alternatively, a 12c T¡A producing a GAA (Fig-
Case 1 
    1st Iteration (TGT)                
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     1st Iteration (GAT)    2nd Iteratio
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Figure 6. Use of Pyromaker-generated pyrosequencing traces, iterative mod
far left, followed by the three alternative second iterations. Only the TTT m
approach to interpret case 2. Only those peaks corresponding to signature p
consistent with the experimental data (either missing peaks or ones that areure 6B, right) also reduces the T peak, but does notincrease the subsequent G peak. In summary, one can
identify a specific mutation in a gene by sequentially
adding mutations to the wild-type sequence to iteratively
reproduce a complex pyrogram.
Melting Curve Analysis and TA Cloning with
Sequencing
We also performed melt curve analysis. For case 1, the
mutant allele demonstrated a melting temperature sub-
stantially lower than the wild-type (15°C) and single
mutation (8°C) control (Figure 7A), consistent with a
single allele with two adjacent mutated bases (TTT)
that are presumably highly destabilizing to the DNA
duplex. However, for case 2 there was a smaller dif-
ference (1.5°C) between the melting temperature for
the double-base mutant allele (GAG) and the single-
base mutant control (G13D, GAC). Two other single-base
mutation controls (TGT, G12C; and TGC, G13C) melted
in the same region as the single-base mutant control
(data not shown).
To unequivocally determine the KRAS mutation se-
quences, we performed TA cloning of PCR products, and
Sanger sequencing of the cloned mutant KRAS plasmids.
Double mutant TTT and GAG mutations were confirmed
for these two cases as expected (Figure 7, B–D).
Some clinical molecular diagnostics laboratories rely
on Qiagen’s KRAS pyrosequencing interpretation soft-
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Pyromaker: A Pyrogram Generator 157
JMD March 2012, Vol. 14, No. 2tions. This software is able to identify mutant peaks and is
proposed to assist and/or to automate the interpretation
of KRAS mutants. When these two complex cases were
tested, the software was unable to correctly identify the
mutations (not shown).
Discussion
Sequencing technologies such as pyrosequencing or
Sanger sequencing occasionally encounter complex re-
sults that are either not interpretable or difficult to inter-
pret. In this report, we provide three strategies to resolve
these issues using KRAS mutation detection as an exam-
ple. We present Pyromaker as a validated tool that gen-
erates virtual pyrograms, and demonstrate that all codon
12 and 13 single and complex mutations generate unique
pyrograms. Notably, some single-base mutations are in-
distinguishable from some complex ones (using the de-
fault dispensation sequence), suggesting that such com-
plex mutations may be underreported.
Pyromaker allows for user-directed hypothesis testing
by generating virtual traces that can be compared with
the actual data. This distinction is important when difficult
or confusing data are encountered for which common
mutants do not offer a sufficient explanation of all of the
features in the pyrogram. In addition, there are no limita-
tions to the kinds of sequences that can be input into
Pyromaker, so the same uses can be applied to pyro-
grams from other assays as the need arises. Given the
fact that the common KRAS mutations are recognized
easily by experienced molecular pathologists, the auto-
mation of simple mutations is less critical than the tools
offered by Pyromaker that are necessary to understand
more complex mutations. Pyromaker may be a useful tool
when designing dispensation sequences for other genes,
in that it allows one to confirm that a proposed dispen-
sation detects all of the mutations.
Before performing the analysis, it was not immediately
obvious that all of the pyrograms for each of the different
codon 12 or 13 mutations must be unique. In fact, some
Melt Curve A
Figure 7. Melting curve analysis and TA cloning/sequencing. A: Melting curv
G12E). Note that for case 1, the melt curve for the mutant allele is 9°C low
about a 1.5°C difference. B–D: TA cloning/sequencing results of single repre
2 (GAG, G12E) (D). Red arrowheads indicate mutant T bases. Green arrare qualitatively highly similar (eg, Figure 1, GAT versusGGA). Because we have highlighted all of the peaks that
are increased and decreased for each of the KRAS
codon 12 and 13 mutations (Figures 1 and 2), quantita-
tive differences that distinguish two qualitatively similar
mutations can be easily identified. We also show that the
pyrograms for all of the currently reported complex mu-
tations (see Supplemental Figures S5 and S6 at http://
jmd.amjpathol.org) are distinct from one another and dis-
tinct from the single-base changes. These may serve as
reference materials for those signing out clinical results. In
fact, we hypothesize that there are only three types of mu-
tations that cannot be resolved by pyrosequencing: i) the
exact location of lost base within a homopolymeric run (eg,
if A9¡A8 is due to loss of the second adenine versus the
sixth adenine); ii) whether a particular pyrogram is due to a
heterozygous mutation in a tumor with 60% cancer cells or
a homozygous mutation in a tumor with 30% cancer cells;
and iii) certain mutations with a dispensation order not de-
signed to distinguish them (eg, AGT versus AAT as dis-
cussed above with the default dispensation).
Because of the sequencing by synthesis nature of
pyrosequencing, cases with more than a single point
mutation can produce complex pyrograms, and addi-
tional methods are needed to definitively identify the
mutation in these cases. Sanger sequencing is clearly
one of the options. For example, with the two cases
presented in this report, Sanger sequencing data allowed
us to list the alternative hypotheses of nucleotide alterations.
Wild type Sanger:    
GGTGGC 
Case 1 Sanger 
Case 2 Sanger 
12 13 
G C T G G T G G C G T A 
G C T T T T G G C G T A 
G C T G A G G G C G T A 
B
C
D
ild-type KRAS, a single mutant control, case 1 (TTT, G12F) and case 2 (GAG,
the single-base GAC, G13D mutant control, whereas for case 2, there is only
e plasmids for wild-type KRAS (GGT) (B), case 1 (TTT, G12F) (C), and case
indicates mutant A base. Black arrowhead indicates mutant G base.
Table 1. Approaches to Resolving Complex Cases
Technology Unambiguous interpretation
Pyro alone No
Sanger alone No
Pyro  Sanger Yes
Pyro  software* Yes
Pyro or Sanger  MCA /†
Pyro or Sanger  C/S Yes
*Software used in iterative mode.
†MCA was clearly distinct for the TTT mutation, but was less obvious
for the GAG mutation.es for w
er thanC/S, cloning and sequencing; MCA, melting curve analysis; Pyro,
pyrosequencing; Sanger, Sanger sequencing.
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mind, we were able to interpret the pyrosequencing pattern
thoroughly and accurately (see Supplemental Figure S7 at
http://jmd.amjpathol.org). Supplemental Figure S8 (avail-
able at http://jmd.amjpathol.org) demonstrates how the
advancing polymerase sequentially adds bases and
generates signals. Thus pyrosequencing and Sanger se-
quencing are one combination that permit unambiguous
interpretation (Table 1), although this adds to the cost
and turn-around time of the testing.
Alternatively, Pyromaker is extremely helpful for quickly
and efficiently testing the possibilities that can explain a
complicated pyrosequencing result. As discussed, the
hypothesis testing mode requires previous Sanger se-
quencing, and thus the iterative mode is preferred. With
only the pyrogram in hand, one can add mutations to the
wild-type sequence sequentially to reproduce the actual
pyrogram (Figure 6, Table 1). This is the most efficient
approach because it can be done with only the experi-
mental pyrogram and the Pyromaker traces and does not
require Sanger sequencing or any other data. It is readily
and freely available online and can be accessed from
any computer with Internet access.
In addition, melting curve analysis may supply helpful
information. The effect of two-base mutations on melting
temperature has not been studied in detail, but it does not
seem to be easily extrapolated from data with single-
base mispairs,18 and it is interesting that the two complex
mutations have very different effects. In this regard, San-
taLucia et al have studied in detail the effects of nearest
neighbors on melting temperature for several specific
mispairs.19 We note that additional optimization on a
more advanced platform might permit this distinction,
especially by using the delta Tm method.20 In this regard,
TA cloning and sequencing provided an unequivocal
interpretation; however, although it is substantially easier
than in the past, it remains somewhat labor intensive, risks
plasmid contamination of the laboratory, may delay report-
ing, and is not routinely used in most clinical molecular
diagnostics laboratories. Without access to pyrosequenc-
ing, TA cloning and sequencing would probably be the best
method for resolving ambiguous Sanger sequencing re-
sults, although limiting dilution PCR should also work. Other
methods can also be used, but interestingly, somemethods
such as allele-specific PCR may not detect these complex
mutations, which may be reported as wild type.
In summary, although pyrosequencing and Sanger se-
quencing are both powerful tools to resolve most muta-
tions, for certain complex cases, neither of them alone is
enough to provide a definitive interpretation. Additional
methods, such as Pyromaker analysis or TA cloning/se-
quencing, allow one to definitively diagnose the mutant
alleles. Iterative Pyromaker analysis is the least expen-
sive and the fastest method for resolving these cases.
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